ArticleRevista peruana de medicina experimental y salud publica2026
Implementation of a SARS-CoV-2 genomic surveillance network as a strategy to face other health challenges in Peru.
Article in Revista peruana de medicina experimental y salud publica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a complete description of the implementation of SARS-CoV-2 genomic surveillance during the COVID-19 pandemic in Peru, and the impact of applying this technology to other pathogens important for the country's public health. This aims to highlight the achievements, challenges, and lessons learned that allow for strengthening the response to current and future health challenges at the national level, as well as public health decisions. With the genomic surveillance initiative led by the National Institute of Health, 48,691 SARS-CoV-2 genomes from all regions of the country have been sequenced from 2020 to 2024, achieving the identification of eight variants of the virus and the designation of 25 new lineages within the Gamma, Delta, and Omicron variants. Genomic surveillance of SARS-CoV-2 has allowed for the timely identification of variants of epidemiological interest, monitoring the evolution of the virus in real-time, and using this information as a tool for public health decision-making. This experience subsequently provided the basis for monitoring other pathogens that have caused health emergencies in Peru and the world, such as dengue, influenza, and mpox.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.